Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson: 2Q Earnings Snapshot

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/16/2019 | 06:49am EDT

NEW BRUNSWICK, N.J. (AP) _ Johnson & Johnson (JNJ) on Tuesday reported second-quarter net income of $5.61 billion.

The New Brunswick, New Jersey-based company said it had net income of $2.08 per share. Earnings, adjusted for one-time gains and costs, came to $2.58 per share.

The results surpassed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of $2.42 per share.

The world's biggest maker of health care products posted revenue of $20.56 billion in the period, also topping Street forecasts. Four analysts surveyed by Zacks expected $20.32 billion.

Johnson & Johnson expects full-year earnings in the range of $8.53 to $8.63 per share.

Johnson & Johnson shares have climbed slightly more than 4% since the beginning of the year, while the Standard & Poor's 500 index has increased 20%. The stock has risen 7% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on JNJ at https://www.zacks.com/ap/JNJ

© 2019 The Canadian Press. All rights reserved., source Canadian Press DataFile

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
08/22JOHNSON & JOHNSON : Now Accepting Global Applications for 2020 Women in STEM2D S..
PU
08/21JOHNSON & JOHNSON : Trump signs student debt forgiveness for disabled veterans
AQ
08/21JOHNSON & JOHNSON : Oklahoma judge expected to rule Monday in opioid case
AQ
08/19JOHNSON & JOHNSON : Congo to use second vaccine to fight Ebola
AQ
08/16JOHNSON & JOHNSON INVESTIGATION UPDA : Kahn Swick & Foti, LLC Continues to Inves..
BU
08/16JOHNSON & JOHNSON : Ebola Crisis-The Vaccines Debate
AQ
08/15JOHNSON & JOHNSON : Janssen Announces European Commission Approval of Imbruvica ..
AQ
08/13JOHNSON & JOHNSON : J&J's Janssen Gets EC OK for Expanded Use of Imbruvica
DJ
08/12JOHNSON & JOHNSON : Thinking about trading options or stock in AbbVie, Bristol-M..
PR
08/12JOHNSON & JOHNSON : Janssen Announces U.S. FDA Accelerated Approval for SIRTURO ..
AQ
More news
Financials (USD)
Sales 2019 81 594 M
EBIT 2019 25 389 M
Net income 2019 18 319 M
Debt 2019 5 892 M
Yield 2019 2,86%
P/E ratio 2019 19,5x
P/E ratio 2020 17,3x
EV / Sales2019 4,32x
EV / Sales2020 4,06x
Capitalization 346 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 148,50  $
Last Close Price 131,27  $
Spread / Highest target 28,7%
Spread / Average Target 13,1%
Spread / Lowest Target -5,54%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.72%346 443
ROCHE HOLDING LTD.12.16%238 668
MERCK AND COMPANY13.49%222 522
NOVARTIS17.97%206 833
PFIZER-20.11%192 868
NOVO NORDISK AS15.68%123 385